22 research outputs found
Hydrogen production from the catalytic supercritical water gasification of process water generated from hydrothermal liquefaction of microalgae
The integration of hydrothermal liquefaction (HTL) and hydrothermal gasification (HTG) is an option for enhanced energy recovery and potential biocrude upgrading. The yields and product distribution obtained from the HTL of Chlorella vulgaris have been investigated. High conversion of algae to biocrude as well as near complete gasification of the remaining organic components in the aqueous phase was achieved. The aqueous phase from HTL was upgraded through catalytic HTG under supercritical water conditions to maximise hydrogen production for biocrude hydrotreating. High yields of hydrogen were produced (∼30 mol H2/kg algae) with near complete gasification of the organics (∼98%). The amount of hydrogen produced was compared to the amounts needed for complete hydrotreating of the biocrude. A maximum of 0.29 g H2 was produced through HTG per gram of biocrude produced by HTL. The nutrient content of the aqueous phase was analysed to determine suitability of nutrient recovery for algal growth. The results indicate the successful integration of HTL and HTG to produce excess hydrogen and maintain nutrient recovery for algal growth
Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and predicted phenotypes in 33 native and
admixed populations from Ibero-America (n > 6,000) in the context of genetic ancestry (n = 3,387). Continental
ancestries are the major determinants of frequencies of the increased-activity allele CYP2C19*17 and CYP2C19
gUMs (negatively associated with Native American ancestry), decreased-activity alleles CYP2D6*41 and CYP2C9*2
(positively associated with European ancestry), and decreased-activity alleles CYP2D6*17 and CYP2D6*29 (positively
associated with African ancestry). For the rare alleles, CYP2C9*2 and CYPC19*17, European admixture accounts
for their presence in Native American populations, but rare alleles CYP2D6*5 (null-activity), CYP2D6-multiplication
alleles (increased activity), and CYP2C9*3 (decreased-activity) were present in the pre-Columbian Americas.
The study of a broad spectrum of Native American populations from different ethno-linguistic groups show how
autochthonous diversity shaped the distribution of pharmaco-alleles and give insights on the prevalence of clinically
relevant phenotypes associated with drugs, such as paroxetine, tamoxifen, warfarin, and clopidogrel
Additional file 1: of Identification of a blood-borne miRNA signature of synovial sarcoma
Demographic patient data and blood count of patients with active sarcoma and control groups. Demographic patient data (age, BMI) and blood count (hemoglobin level, platelet count and leukocyte count) of patients with active synovial sarcoma compared to healthy donors, patients with synovial sarcoma in remission and patients with active leiomyosarcoma, MPNST, Ewing sarcoma and liposarcoma. Data are presented as mean value ± standard error of mean (SEM). p- values were determined using a Student’s t-test for independent samples. Hb = Hemoglobin. BMI = Body Mass Index. (PPTX 68 kb
Additional file 5: of Identification of a blood-borne miRNA signature of synovial sarcoma
Comparison of whole blood miRNA expression levels of patients with active synovial sarcoma and miRNA expression levels of corresponding synovial sarcoma tissue. MiRNA-expression of patients with synovial sarcoma expressing SS18-SSX2 are marked in purple. A. miR-99a-5p. B. miR-146b-5p. C. miR-148b-3p. D. miR-195-5p. E. miR-223-3p. F. miR-500b-3p. G. miR-505-3p. (JPEG 2837 kb
Additional file 4: of Identification of a blood-borne miRNA signature of synovial sarcoma
Illustration of the miRNA-expression levels of the two active synovial sarcoma patients who received chemotherapy (Patient 2 and 3 of the screening cohort of active synovial sarcoma patients as depicted in Additional file 3 ) marked with a triangle, patients receiving anticoagulation (Patient 3 of the screening cohort of active synovial sarcoma patients and Patient 1 of the independent cohort of active synovial sarcoma patients as depicted in Additional file 3 ) marked in green and patients receiving radiotherapy/presenting localized disease (Patient 1 of the screening cohort of active synovial sarcoma patients as depicted in Additional file 3 ) marked in red. A, C, E, G, I, K and M include the screening cohort of active synovial sarcoma patients, B, D, F, H, J, L and N depict the independent cohort (IC) of synovial sarcoma patients. (JPEG 5044 kb
Additional file 3: of Identification of a blood-borne miRNA signature of synovial sarcoma
Disease and therapy status of sarcoma patients. M0 = localized disease. M1 = metastatic disease. Current chemotherapy/radiotherapy involves treatment within the last 6 weeks. (PPTX 67 kb